Panacea Global (HOML) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014
Document and Entity Information:	'
Entity Registrant Name	'PANACEA GLOBAL, INC.
Document Type	'10-Q
Document Period End Date	30-Sep-14
Amendment Flag	'false
Entity Central Index Key	'0001024048
Current Fiscal Year End Date	'--12-31
Entity Common Stock, Shares Outstanding	106,747,586
Entity Filer Category	'Smaller Reporting Company
Entity Current Reporting Status	'Yes
Entity Voluntary Filers	'No
Entity Well-known Seasoned Issuer	'No
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q3

Panacea_Global_Inc_Balance_She

Panacea Global, Inc. - Balance Sheets (USD $)	Sep. 30, 2014		Dec. 31, 2013
Current Assets:	'		'
Cash	$52,208		$2,309,563
Accounts receivable	123,566		38,407
Accounts receivable, related party	292,895	[1]	133,531	[1]
Prepaid expenses	13,550		10,633
TOTAL CURRENT ASSETS	482,219		2,492,134
Property and equipment, net	78,110	[2]	78,236	[2]
Equity method investment	909,968	[3]	911,672	[3]
Intangible asset, net	50,000,000	[4]	50,000,000	[4]
Total Assets	51,470,297		53,482,042
LIABILITIES	'		'
Accounts payable and accrued liabilities, current	331,255		390,074
Deferred revenue, current	1,000,000	[3]	1,000,000	[3]
License fee payable, current	'	[4]	574,211	[4]
Due to related parties, current	986,453	[1]	853,740	[1]
TOTAL LIABILITIES	2,317,708		2,818,025
Stockholders' Equity	'		'
Preferred Stock	0	[5]	0	[5]
Capital Stock	106,748	[6]	105,998	[6]
Additional paid-in capital	56,322,833		55,145,783
Accumulated deficit	-7,331,646		-4,720,970
Accumulated other comprehensive income	54,654		133,206
Total Stockholders' Equity	49,152,589		50,664,017
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$51,470,297		$53,482,042
[1]	See Note 9
[2]	See Note 4
[3]	See Note 5
[4]	See Note 6
[5]	$0.001 par value; 100,000 shares authorized, none issued; See Note 7
[6]	$0.001 par value; 300,000,000 shares authorized; 106,747,586 issued and outstanding (December 31, 2013- 105,997,586); See Note 7

Statement_of_Financial_Positio

Statement of Financial Position - Parenthetical (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position	'	'
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares Issued	106,747,586	105,997,586
Common Stock, Shares Outstanding	106,747,586	105,997,586
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	100,000	100,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Panacea_Global_Inc_Statements_

Panacea Global, Inc. - Statements of Operations (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Income Statement	'		'		'		'
Revenue	'		'		'		'
EXPENSES	'		'		'		'
General and administrative	677,249		336,063		2,595,835		836,601
Depreciation	4,401		5,235		13,137		14,584
TOTAL OPERATING EXPENSES	681,650		341,298		2,608,972		851,185
(Income) loss from equity investment- basic and diluted	-24	[1]	-113	[1]	-1,704	[1]	5,533	[1]
Net Loss	-681,674		-341,411		-2,610,676		-845,652
Loss per common share-basic and diluted	($0.01)		$0		($0.02)		($0.01)
Weighted number of common shares outstanding- basic and diluted	106,747,586		98,133,872		106,302,531		97,551,962
Other Comprehensive Loss	'		'		'		'
Net Loss	-681,674		-341,411		-2,610,676		-845,652
Foreign currency translation gain (loss)	24,991		-42,732		-78,552		-22,079
Total Other Comprehensive Loss	($656,683)		($384,143)		($2,689,228)		($867,731)
[1]	See Note 5

Panacea_Global_Inc_Statements_1

Panacea Global, Inc. - Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
Cash flows from Operating Activities	'		'
Net Loss	($2,610,676)		($845,652)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Stock-based compensation	1,177,800		20,000
Depreciation	13,137		14,584
Loss (income) from equity method investment	1,704	[1]	-5,533	[1]
Change in assets and liabilities:	'		'
Accounts receivable, increase decrease	-85,159		24,404
Prepaid expenses, increase decrease	-2,917		-17,180
Accounts payable and accrued liabilities, increase decrease	-58,819		-103,343
License fee payable, increase decrease	-574,211		-491,629
Net cash used in operating activities	-2,139,141		-1,404,349
Cash Flows from Investing Activities	'		'
Purchases of property and equipment	-13,011		-14,620
Net cash used in investing activities	-13,011		-14,620
Cash Flows From Financing Activities	'		'
Issuance of common stock for cash	'		1,709,092
Proceeds (payment) from (to) related parties, net	-26,651		-201,852
Net cash provided by (used in) financing activities	-26,651		1,507,240
Effect of exchange rate on cash	-78,552		-22,079
Net change in cash	-2,257,355		66,192
Cash, Beginning of Period	2,309,563		109,151
Cash, End of Period	52,208		175,343
Supplemental Disclosures of Cash Flow Information:	'		'
Interest paid	'		'
Taxes paid	'		'
[1]	See Note 5

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Notes	'
Basis of Presentation	'
	1.                    BASIS OF PRESENTATION
	The accompanying unaudited interim consolidated financial statements of Panacea Global Inc. (the “Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s latest annual report filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the unaudited interim consolidated financial statements that would substantially duplicate the disclosures contained in the audited consolidated financial statements for fiscal year 2013, as reported in the Form 10-K, have been omitted.
	The Company has not earned any revenues from limited principal operations and accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise".
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended September 30, 2014.

Going_Concern

Going Concern	9 Months Ended
	Sep. 30, 2014
Notes	'
Going Concern	'
	2.                    GOING CONCERN
	These unaudited interim consolidated financial statements have been prepared assuming the Company will continue as a going-concern. The Company has incurred losses since inception and the ability of the Company to continue as a going-concern depends upon its ability to raise additional financing to fund its operations and develop profitable operations. Accumulated net losses from inception to September 30, 2014 totaled $7,331,646.  In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing. There is no assurance that the Company will be able to obtain such financing. These conditions create significant doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Notes	'
Summary of Significant Accounting Policies	'
	3.                    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The accounting policies of the Company are in accordance with accounting principles generally accepted in the United States. Presented below are those policies considered particularly significant:
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known. The accounting estimates that require management’s most significant judgments are the valuation of the intangible asset and measurement of accrued liabilities.
	Reclassifications
	Certain reclassifications have been made to amounts in prior periods to conform to the current period presentation. All reclassifications have been applied consistently to the periods presented.
	Basis of Consolidation
	The accompanying interim consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries, Panacea (a Delaware incorporated Company) and Panacea Global Inc. (a Canadian incorporated Company). All inter-company transactions and balances have been eliminated upon consolidation.
	Impairment of Long-lived Assets
	In accordance with ASC 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value of asset less cost to sell. The Company evaluated the Global Diagnostic License on September 30, 2014 and noted no impairment.
	Foreign Currency Translation
	The functional currency of the Company is Canadian dollars. The functional currency of the Company’s subsidiaries is United States dollars. The interim financial statements of the Company have been translated into United States dollars by translating balance sheet accounts at period end exchange rates except for non-current assets which are translated at historical exchange rates, and statement of operations accounts at average exchange rates for the periods. Foreign currency translation gains and losses are reflected in the equity section of the Company’s consolidated balance sheets in Accumulated Other Comprehensive Income (Loss).
	Earnings or Loss Per Share
	The Company accounts for earnings per share pursuant to ASC 260-10-05, Earnings per Share, which requires disclosure on the financial statements of "basic" and "diluted" earnings (loss) per share. Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding plus common stock equivalents (if dilutive) related to stock options and warrants for each period.  In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive.
	Income Taxes
	The Company accounts for income taxes pursuant to ASC 740-10, Accounting for Income Taxes. Deferred tax assets and liabilities are recorded for differences between the financial statements and tax basis of the assets and liabilities as well as loss carry forward that will result in taxable or deductible amounts in the future based on enacted tax laws and rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is recorded for the amount of income tax payable or refundable for the period increased or decreased by the change in deferred tax assets and liabilities during the period.
	Stock-based Compensation
	The Company follows ASC 718, Share-Based Payment, which establishes standards for transactions in which an entity exchanges its equity instruments for goods and services. This standard focuses primarily on accounting for transactions in which an entity obtains employee services in stock-based payment transactions, including issuance of stock options to employees. The Company measures stock-based compensation cost at grant date, based on the estimated fair value of the award, and recognizes the cost as expense (net of estimated forfeitures) over the expected service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model.
	Investment in Equity Instruments
	The Company has accounted for its investment in equity and debt securities using the equity method of accounting based on the guidelines established in FASB ASC 323. In applying the guidance of FASB ASC 323, the Company recognizes the investment in stock of an investee as an asset. The asset is recorded initially at cost in accordance with the guidance in FASB ASC 805-50-30. The Company will recognize its share of the earnings or losses of an investee in the periods for which they are reported by the investee in its financial statements. The Company adjusts the carrying value of the investment for its share of the earnings or losses of the investee after the date of investment and shall report the recognized earnings or losses in the consolidated statements of operations.
	Subsequent Events
	The Company has evaluated all transactions through the financial statement issuance date for subsequent event disclosure consideration.
	Recent Accounting Pronouncements
	The Company has assessed the applicability and impact of all recently issued accounting pronouncements and they have been determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position, results of operations, or cash flows.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Notes	'
Property and Equipment	'
	4.                   PROPERTY AND EQUIPMENT
			As at September 30, 2014
		Useful	Cost	Accumulated Depreciation	Net Book Value
		Lives (yrs)
	Leasehold improvements	10	$   84,816	$     36,477	$    48,339
	Furniture & equipment	7	28,652	8,262	20,390
	Lab equipment	5	14,448	5,626	8,822
	Computer equipment	2.5	1,820	1,261	559
	Total		$129,736	$   51,626	$    78,110
			As at December 31, 2013
		Useful	Cost	Accumulated Depreciation	Net Book Value
		Lives (yrs)
	Leasehold improvements	10	$   79,866	$     28,516	$      51,350
	Furniture & equipment	7	20,001	5,659	14,342
	Lab equipment	5	14,448	2,628	11,820
	Computer equipment	2.5	1,820	1,096	724
	Total		$116,135	$    37,899	$    78,236
	During the three and nine months ended September 30, 2013 and 2014, the Company recorded depreciation expense of $5,235, $4,401, $14,584, and $13,137, respectively.

Equity_Method_Investment

Equity Method Investment	9 Months Ended
	Sep. 30, 2014
Notes	'
Equity Method Investment	'
	5.                   EQUITY METHOD INVESTMENT
	Sublicense Agreement
	On November 18, 2011, the Company entered into a sublicense agreement with Panacea Laboratories, Inc. (“Laboratories”) to sublicense the rights to develop, market and use licensed products related to Human Aspartyl (Asparaginyl) B-Hydroxylase (“HAAH”) based laboratory tests in Canada.
	In consideration for the rights received under the sublicense agreement, Laboratories provided the Company with 40,000,000 shares of its common stock and will pay the Company a sublicense fee of $960,000, due within 3 years.  The fair value of the aggregate consideration paid and therefore the initial cost of the investment equated to $1,000,000, which was recognized as the initial asset balance of the investment.  Further, Laboratories must purchase all conforming reagents from the Company at a cost of $20 per test or 10% of the sale price of the individual test with a minimum $8.00 test price.
	Sublicensing revenues of $1,000,000 had been recorded in deferred revenues at December 31, 2011 and will be taken into revenues once Laboratories commences operations. The amount of deferred revenues is unchanged since December 31, 2013. Upon the recognition of revenue, the Company will recognize its liability to reimburse Panacea Pharmaceuticals 25% of all sublicensing revenue as disclosed above under the terms of the license agreement.
	Based on the accounting guidance of FASB ASC 323, the Company’s investment in Laboratories was subsequently decreased due to the Company’s share of the losses in Laboratories’ operations. The Company’s investment of 40,000,000 common shares represents a 50% ownership interest in Laboratories. Laboratories intends to raise capital in the current year through issuing additional shares and the Company’s ownership interest in Laboratories is expected to decline.  The Company has significant influence over Laboratories but does not have the level of control that would require consolidation and has thus accounted for its investment in Laboratories using the equity method.
	Equity Investment in Laboratories
	Balance, December 31, 2013		911,672
	Share of equity in loss for the nine months ended September 30, 2014		-1,704
	Balance, September 30, 2014	$	909,968
	Set out below is the summarized financial information of Laboratories at September 30, 2014, which is accounted for using the equity method. The information reflects the amounts presented in the financial statements of Laboratories adjusted for differences in accounting policies between the Company and Laboratories. Our share of income and losses from our equity method investment in Laboratories is included in loss from equity investment in the consolidated statements of operations and other comprehensive loss.
	Summarized Balance Sheets
		30-Sep-14		31-Dec-13
	Assets
	Current Assets
	Cash	$     111,408		$     (8,569)
	Total Current Assets	111,408		-8,569
	Intangible assets- license	1,025,152		1,025,152
	Total Assets	$  1,136,560		$   1,016,583
	Liabilities
	Current Liabilities
	Accounts payable	$      17,574		$       43,300
	Due to Panacea Global – related party	199,111		50,000
	Total Current Liabilities	216,685		93,300
	License fees payable	976,320		976,320
	Total Liabilities	1,236,623		1,069,620
	Commitments and contingencies
	Stockholders’ Deficit
	Common stock	80,000		80,000
	Additional paid in capital	43,618		43,618
	Accumulated deficit	-180,063		-176,655
	Total Stockholders’ Deficit	-100,063		-53,037
	Total Liabilities and Stockholders’ Equity	$  1,136,560		$  1,016,583
	Summarized Statements of Operations
		For the Three Months Ended September 30,			For the Nine Months Ended September 30,
		2014		2013	2014	2013
	Revenue	$                 -		$     11,455	$                 -	$      11,455
	Operating Expense
	General and administrative	48		11,681	3,408	389
	Total Operating Expenses	48		11,681	3,408	389
	Net Income (Loss)	$           (48)		$        (226)	$      (3,408)	$      11,066

Intangibles_and_License_Fee_Pa

Intangibles and License Fee Payable	9 Months Ended
	Sep. 30, 2014
Notes	'
Intangibles and License Fee Payable	'
	6.                INTANGIBLES AND LICENSE FEE PAYABLE
	License Agreement
	On March 24, 2010, the Company entered into a license agreement with Panacea Pharmaceuticals Inc. (“Pharmaceuticals”), a related party, to acquire the global diagnostic license (“GDL”), with rights to sublicense worldwide, except for the United States of America. GDL allows the Company to develop, market and use licensed products related to HAAH based laboratory tests.
	In consideration for the GDL, the Company issued 35,500,000 common shares and will pay Pharmaceuticals a license fee of $2,500,000, due within 30 days of the Company raising a minimum $10,000,000 equity investment.  One-half of any equity investments raised shall be remitted to Pharmaceuticals, until the license fee is paid in full. The aggregate consideration paid and therefore fair value of the GDL equates to $50,000,000.  Further, the Company will pay Pharmaceuticals 25% of all sublicensing revenue and will purchase all conforming reagent at a cost of $20 per test or 10% of the sale price of the individual test with a minimum of an $8 test price.
	The GDL contains certain issued and pending patent rights. Upon commencement of licensed services to customers, amortization will be taken over the estimated useful life of the respective patent rights, which vary and are determined on a country-by-country basis.
	As of September 30, 2014, the Company had not commenced any services relating to GDL and as a result, no amortization has been recorded.
	As of September 30, 2014, management evaluated whether events and circumstances have occurred that indicate possible impairment and concluded that no impairment was noted.
	License Fee Payable
	The Company made license fee payments to Laboratories of $636,100 for the nine months ended September 30, 2014 to reduce the license fee payable from $574,211 as of December 31, 2013 to $0, and have recorded a receivable of $61,889 as of September 30, 2014 included in accounts receivable.

Capital_Stock

Capital Stock	9 Months Ended
	Sep. 30, 2014
Notes	'
Capital Stock	'
	7.                    CAPITAL STOCK
	Common Shares
	During the nine months ended September 30, 2013, the following common shares were issued by the Company for cash:
	·         On April 29, 2013, 1,184,000 common shares issued for proceeds of $592,000.
	·         On May 31, 2013, 860,000 common shares for proceeds of $380,000.
	·         On June 4, 2013, 20,000 common shares for proceeds of $10,000.
	·         On July 8, 2013, 680,000 common shares for proceeds of $287,105.
	·         On July 26, 2013, 100,000 common shares for proceeds of $50,000.
	·         On August 13, 2013, 100,000 common shares for proceeds of $50,000.
	On March 1, 2013, the Company issued 40,000 common shares for services valued at $20,000 based on the grant date fair value.
	On July 9, 2014, the Company issued 750,000 common shares for services valued at $375,000, based on the grant date fair value, and recorded stock-based compensation.
	Warrants
	The following table provides information on the Company’s warrants as of September 30, 2014.  Each warrant provides the warrant holder the option to purchase one share.
		Number of Warrants	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value
	Outstanding at December 31, 2013	500,000	$0.25	2	$-
	Granted	-
	Exercised	-
	Expired	(500,000)	$0.25	0
	Outstanding at September 30, 2014	-			$-
	During the nine months ended September 30, 2013, the following commons shares were issued by the Company from the exercise of warrants:
	·         On February 25, 2013, 200,000 common shares for cash of $50,000.
	·         On February 28, 2013, 200,000 common shares for cash of $50,000.
	·         On March 22, 2013, 200,000 common shares for cash of $50,000.
	·         On March 27, 2013, 600,000 common shares for cash of $152,895.
	·         On May 22, 2013, 200,000 common shares for cash of $50,000.
	Options
	On April 10, 2014, the Company granted 1,300,000 options, with a fair market value of $802,800, based on the grant date fair value, to officers, directors and consultants of the Company as incentive compensation. The options vested and became exercisable on April 10, 2014 at an exercise price of $0.55 per share and expire on April 10, 2016.
	The fair value of each option granted was estimated on the date of the grant using the Black-Scholes fair value option pricing model with the following assumptions: fair value of options of $0.62, risk-free rate of 0.37%, expected life of the options of two years, annualized volatility of 242%, and no expected dividends. Volatility was determined based on daily observations of the historical stock price over a period consistent with the expected life of the options at the date of grant.
	Stock-based compensation of $0 and $802,800, respectively, was expensed during the three and nine months ended September 30, 2014 relating to current period grants ($0 during the three months ended and $0 during the nine months ended September 30, 2013).
		Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value
	Outstanding at December 31, 2013	4,500,000	$0.55	7.57	$   -
	Granted	1,300,000	$0.55	1.53
	Exercised	-
	Expired	-
	Outstanding at September 30, 2014	5,800,000	$0.55	5.64	$   -
	As of September 30, 2014, there was no unrecognized compensation related to non-vested options.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Notes	'
Income Taxes	'
	8.                   INCOME TAXES
	The Company accounts for income taxes in accordance with ASC 740-20. ASC 740-20 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates. The effects of future changes in tax laws or rates are not anticipated.
	Under ASC 740-20 income taxes are recognized for the following: a) amount of tax payable for the current year, and b) deferred tax liabilities and assets for future tax consequences of events that have been recognized differently in the financial statements than for tax purposes.
	The Company has income tax losses of approximately $5,000,000 available to be applied against future year’s income as a result of the losses incurred since inception. However, due to the losses incurred since inception and expected future operating results, management determined that it is more likely than not that the deferred tax asset resulting from the tax losses available for carry forward will not be realized through the reduction of future income tax payments. Accordingly a 100% valuation allowance has been recorded for income tax losses available for carry forward.
	As of September 30, 2014, the Company did not have any amounts recorded pertaining to uncertain tax positions.  The Company files federal and provincial income tax returns in Canada and federal, state and local income tax returns in the U.S., as applicable.  The Company may be subject to a reassessment of federal and provincial income taxes by Canadian tax authorities for a period of three to five years from the date of the original notice of assessment in respect of any particular taxation year.  In certain circumstances, the U.S. federal statute of limitations can reach beyond the standard three year period.  U.S. state statutes of limitations for income tax assessment vary from state to state.

Related_Party_Transacations

Related Party Transacations	9 Months Ended
	Sep. 30, 2014
Notes	'
Related Party Transacations	'
	9.                   RELATED PARTY TRANSACATIONS
	During the nine months ended September 30, 2014, the Company paid back amounts due to related parties, which had been advanced in the past to fund its operating and investing activities.  Amounts due to related parties are due on demand, are non-interest bearing and approximate fair value due to their short term to maturity. Amounts due from Dr. Moshiri, CEO, and Dr. Ghanbari relate to advances for business related travel and are short-term in nature. Amounts due from Dr. Stead relate to advances for product-related research costs. Amounts due to (from) related parties as of September 30, 2014 and December 31, 2013 are as follows:
	Accounts receivable – related parties	30-Sep-14	31-Dec-13
	Due from Dr. Stead	$        62,454	$                  -
	Due from Dr. Ghanbari	52,795	55,635
	Due from Panacea Laboratories	177,646	77,896
	Total	$      292,895	$      133,531
	Due to related parties	30-Sep-14	31-Dec-13
	Due to Dr. Moshiri, CEO of the Company	$      178,440	$           2,256
	Due to 668152 Ontario Ltd.	808,013	851,484
	Total	$      986,453	$      853,740

Lease_Commitments

Lease Commitments	9 Months Ended
	Sep. 30, 2014
Notes	'
Lease Commitments	'
	10.                LEASE COMMITMENTS
	In 2011, the Company entered into a lease for premises in Toronto, Ontario.  The lease term is 60 months. Rent expense under all operating leases was approximately $54,407and $246,062  for the nine months ended September 30, 2014 and 2013 respectively.
	In addition, the Company is required to pay its pro rata share of common area maintenance costs and property taxes.

Legal_Contingencies

Legal Contingencies	9 Months Ended
	Sep. 30, 2014
Notes	'
Legal Contingencies	'
	11.                LEGAL CONTINGENCIES
	Moneylogix Group, Inc. et al. v. Panacea Global, Inc. et al.
	On October 7, 2011, Moneylogix Group, Inc., Maximus Investments, Inc., Bakirkoy Financial Holdings, Inc., Bowen Financial Advisory Group LTD., Marciafor Holdings, Inc., Alex Haditaghi and Gary Cilevitz (collectively, the “Moneylogix Plaintiffs”) filed a lawsuit in the Superior Court of Justice in Ontario, Canada against the Company and other parties. The Moneylogix Plaintiffs generally allege that the Company breached its obligations pursuant to a Consulting Agreement and various verbal agreements regarding the Share Exchange Agreement.  The Company, on August 20, 2013, filed a Statement of Claim with the Ontario Superior Court of Justice against the Moneylogix Plaintiffs.
	For procedural reasons, the Company’s Statement of Claim was discontinued and replaced by a Statement of Defence and Counterclaim, which the Court has also deemed filed on August 20, 2013. There have been no material developments in this litigation since the filing of the Statement of Defence and Counterclaim.  The Company believes the Moneylogix Plaintiffs’ claims against it are entirely without merit and intends to continue to vigorously defend itself against and pursue, as applicable, its legal recourses against the Moneylogix Plaintiffs in court.
	Baywood Homes Partnership et al. v. Moneylogix Group, Inc. et al.
	On September 9, 2010, Baywood Homes Partnership, 2131059 Ontario Limited, 2206659 Ontario Limited, 2147789 Ontario Limited, 1367169 Ontario Limited and Ralph Canonaco (collectively, the " Baywood Plaintiffs") filed a lawsuit in the Superior Court of Justice in Ontario, Canada against Alex Haditaghi, Majid Haditaghi, Moneylogix Group, Inc. (a Canadian company), Mortgagebrokers.com, Financial Group of Companies Inc., Gary Cilevitz, Michael Knarr, and Farideh Ronhbakhsh (the “Baywood Non-Company Defendants”) and the Company.  As previously disclosed, the Company did not participate in the initial defence put forth by the Baywood Non-Company Defendants.  On April 18, 2013, Justice Edward Belobaba granted, in part, the Baywood Non-Company Defendants’ summary judgment motion and dismissed the Baywood Plaintiffs’ action in its entirety.  Justice Belobaba denied the Baywood Non-Company Defendants’ summary judgment motion with regard to granting their counter-claim against the Baywood Plaintiffs.   On June 9, 2014, Justice Belobaba’s decision was reversed on appeal.  The litigation, in its entirety will now proceed against all defendants.  The Company believes that the Baywood Plaintiff’s claims against it are entirely without merit and intends to vigorously defend itself against and pursue, as applicable, its legal recourses against the Baywood Plaintiffs in court.
	Panacea Global, Inc. et-al. v. Moneylogix Group, Inc. et-al.
	On September 24, 2013, the Company, Panacea Pharmaceuticals, Inc., a corporation organized under the laws of the State of Maryland and a principal shareholder of the Company, Mahmood Moshiri, the Company's Chief Executive Officer, President, Chief Medical Officer, Interim Chief Financial Officer and Director, and Binnay Sethi, the Company's Vice President and also a Director (collectively, the “Panacea Global Plaintiffs”) filed a lawsuit in the Superior Court of Justice in Ontario, Canada against Alex Haditaghi, Gary Cilevitz, Lateral Management Corp, I Stock Daily Inc., Daniel Putnam, Marcelle Lean, Mike Knarr, Mark Lindsay, Dong-Soo Lee, Robert Hyde, David Nelson, Vince Calicha, Stephen Conville, and Joseph Ferraro (collectively, the “Panacea Global Defendants”).
	The Panacea Global Plaintiffs allege that the Panacea Global Defendants, prior to the entering into of the Share Exchange Agreement, conspired to cause the entity then known as Moneylogix Group, Inc., a Nevada Corporation (“Moneylogix USA” and the entity that is now the Company), to issue a substantial number of shares to Ferraro and Lateral Management Corp. for no or otherwise inadequate consideration.  In addition, the Panacea Global Plaintiffs allege that after the entering into of the Share Exchange Agreement, Cilevitz wrote a letter to Moneylogix USA’s transfer agent in which he engaged in fraudulent misrepresentation in order to cause Moneylogix USA to improperly issue 1,000,000 shares to Putnam, Lateral Management Corp., Lean, Knarr, Lindsay, Lee, Hyde, Nelson, I Stock, Calicha, and Conville for no or otherwise insufficient consideration.
	The Panacea Global Plaintiffs seek a number of different forms of relief, including general damages in the amount of approximately $10 million, exemplary or punitive damages in the amount of approximately $1 million, and the cancellation of certain shares.  The Panacea Global Defendants have not yet delivered a Statement of Defence. The Company intends to vigorously pursue its legal recourses against the Panacea Global Defendants in court.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies: Use of Estimates (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known. The accounting estimates that require management’s most significant judgments are the valuation of the intangible asset and measurement of accrued liabilities.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies: Reclassifications (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to amounts in prior periods to conform to the current period presentation. All reclassifications have been applied consistently to the periods presented.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies: Basis of Consolidation (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Basis of Consolidation	'
	Basis of Consolidation
	The accompanying interim consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries, Panacea (a Delaware incorporated Company) and Panacea Global Inc. (a Canadian incorporated Company). All inter-company transactions and balances have been eliminated upon consolidation.

Summary_of_Significant_Account4

Summary of Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Impairment of Long-lived Assets	'
	Impairment of Long-lived Assets
	In accordance with ASC 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value of asset less cost to sell. The Company evaluated the Global Diagnostic License on September 30, 2014 and noted no impairment.

Summary_of_Significant_Account5

Summary of Significant Accounting Policies: Foreign Currency Translation (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Foreign Currency Translation	'
	Foreign Currency Translation
	The functional currency of the Company is Canadian dollars. The functional currency of the Company’s subsidiaries is United States dollars. The interim financial statements of the Company have been translated into United States dollars by translating balance sheet accounts at period end exchange rates except for non-current assets which are translated at historical exchange rates, and statement of operations accounts at average exchange rates for the periods. Foreign currency translation gains and losses are reflected in the equity section of the Company’s consolidated balance sheets in Accumulated Other Comprehensive Income (Loss).

Summary_of_Significant_Account6

Summary of Significant Accounting Policies: Earnings Or Loss Per Share (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Earnings Or Loss Per Share	'
	Earnings or Loss Per Share
	The Company accounts for earnings per share pursuant to ASC 260-10-05, Earnings per Share, which requires disclosure on the financial statements of "basic" and "diluted" earnings (loss) per share. Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding plus common stock equivalents (if dilutive) related to stock options and warrants for each period.  In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive.

Summary_of_Significant_Account7

Summary of Significant Accounting Policies: Income Taxes (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes pursuant to ASC 740-10, Accounting for Income Taxes. Deferred tax assets and liabilities are recorded for differences between the financial statements and tax basis of the assets and liabilities as well as loss carry forward that will result in taxable or deductible amounts in the future based on enacted tax laws and rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is recorded for the amount of income tax payable or refundable for the period increased or decreased by the change in deferred tax assets and liabilities during the period.

Summary_of_Significant_Account8

Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Stock-based Compensation	'
	Stock-based Compensation
	The Company follows ASC 718, Share-Based Payment, which establishes standards for transactions in which an entity exchanges its equity instruments for goods and services. This standard focuses primarily on accounting for transactions in which an entity obtains employee services in stock-based payment transactions, including issuance of stock options to employees. The Company measures stock-based compensation cost at grant date, based on the estimated fair value of the award, and recognizes the cost as expense (net of estimated forfeitures) over the expected service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model.

Summary_of_Significant_Account9

Summary of Significant Accounting Policies: Investment in Equity Instruments (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Investment in Equity Instruments	'
	Investment in Equity Instruments
	The Company has accounted for its investment in equity and debt securities using the equity method of accounting based on the guidelines established in FASB ASC 323. In applying the guidance of FASB ASC 323, the Company recognizes the investment in stock of an investee as an asset. The asset is recorded initially at cost in accordance with the guidance in FASB ASC 805-50-30. The Company will recognize its share of the earnings or losses of an investee in the periods for which they are reported by the investee in its financial statements. The Company adjusts the carrying value of the investment for its share of the earnings or losses of the investee after the date of investment and shall report the recognized earnings or losses in the consolidated statements of operations.

Recovered_Sheet1

Summary of Significant Accounting Policies: Subsequent Events (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Subsequent Events	'
	Subsequent Events
	The Company has evaluated all transactions through the financial statement issuance date for subsequent event disclosure consideration.

Recovered_Sheet2

Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2014
Policies	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company has assessed the applicability and impact of all recently issued accounting pronouncements and they have been determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position, results of operations, or cash flows.

Property_and_Equipment_Propert

Property and Equipment: Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules	'
Property, Plant and Equipment	'
			As at September 30, 2014
		Useful	Cost	Accumulated Depreciation	Net Book Value
		Lives (yrs)
	Leasehold improvements	10	$   84,816	$     36,477	$    48,339
	Furniture & equipment	7	28,652	8,262	20,390
	Lab equipment	5	14,448	5,626	8,822
	Computer equipment	2.5	1,820	1,261	559
	Total		$129,736	$   51,626	$    78,110
			As at December 31, 2013
		Useful	Cost	Accumulated Depreciation	Net Book Value
		Lives (yrs)
	Leasehold improvements	10	$   79,866	$     28,516	$      51,350
	Furniture & equipment	7	20,001	5,659	14,342
	Lab equipment	5	14,448	2,628	11,820
	Computer equipment	2.5	1,820	1,096	724
	Total		$116,135	$    37,899	$    78,236

Equity_Method_Investment_Equit

Equity Method Investment: Equity Investment in Laboratories (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules	'
Equity Investment in Laboratories	'
	Equity Investment in Laboratories
	Balance, December 31, 2013		911,672
	Share of equity in loss for the nine months ended September 30, 2014		-1,704
	Balance, September 30, 2014	$	909,968

Equity_Method_Investment_Summa

Equity Method Investment: Summarized Balance Sheets Text Block (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules	'
Summarized Balance Sheets Text Block	'
		30-Sep-14	31-Dec-13
	Assets
	Current Assets
	Cash	$     111,408	$     (8,569)
	Total Current Assets	111,408	-8,569
	Intangible assets- license	1,025,152	1,025,152
	Total Assets	$  1,136,560	$   1,016,583
	Liabilities
	Current Liabilities
	Accounts payable	$      17,574	$       43,300
	Due to Panacea Global – related party	199,111	50,000
	Total Current Liabilities	216,685	93,300
	License fees payable	976,320	976,320
	Total Liabilities	1,236,623	1,069,620
	Commitments and contingencies
	Stockholders’ Deficit
	Common stock	80,000	80,000
	Additional paid in capital	43,618	43,618
	Accumulated deficit	-180,063	-176,655
	Total Stockholders’ Deficit	-100,063	-53,037
	Total Liabilities and Stockholders’ Equity	$  1,136,560	$  1,016,583

Equity_Method_Investment_Summa1

Equity Method Investment: Summarized Statement of Operations Text Block (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules	'
Summarized Statement of Operations Text Block	'
		For the Three Months Ended September 30,		For the Nine Months Ended September 30,
		2014	2013	2014	2013
	Revenue	$                 -	$     11,455	$                 -	$      11,455
	Operating Expense
	General and administrative	48	11,681	3,408	389
	Total Operating Expenses	48	11,681	3,408	389
	Net Income (Loss)	$           (48)	$        (226)	$      (3,408)	$      11,066

Related_Party_Transacations_Sc

Related Party Transacations: Schedule of Accounts, Notes, Loans and Financing Receivable (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules	'
Schedule of Accounts, Notes, Loans and Financing Receivable	'
	Accounts receivable – related parties	30-Sep-14	31-Dec-13
	Due from Dr. Stead	$        62,454	$                  -
	Due from Dr. Ghanbari	52,795	55,635
	Due from Panacea Laboratories	177,646	77,896
	Total	$      292,895	$      133,531

Related_Party_Transacations_Sc1

Related Party Transacations: Schedule of Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules	'
Schedule of Related Party Transactions	'
	Due to related parties	30-Sep-14	31-Dec-13
	Due to Dr. Moshiri, CEO of the Company	$      178,440	$           2,256
	Due to 668152 Ontario Ltd.	808,013	851,484
	Total	$      986,453	$      853,740

Property_and_Equipment_Propert1

Property and Equipment: Property, Plant and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Leasehold Improvements	'	'
Property Plant and Equipment Useful Life	10	10
Deferred Costs, Noncurrent	$84,816	$79,866
Property, Plant and Equipment, Other, Accumulated Depreciation	36,477	28,516
Net Book Value	48,339	51,350
Furniture and Equipment	'	'
Property Plant and Equipment Useful Life	7	7
Deferred Costs, Noncurrent	28,652	20,001
Property, Plant and Equipment, Other, Accumulated Depreciation	8,262	5,659
Net Book Value	20,390	14,342
Lab Equipment	'	'
Property Plant and Equipment Useful Life	5	5
Deferred Costs, Noncurrent	14,448	14,448
Property, Plant and Equipment, Other, Accumulated Depreciation	5,626	2,628
Net Book Value	8,822	11,820
Computer Equipment	'	'
Property Plant and Equipment Useful Life	2.5	2.5
Deferred Costs, Noncurrent	1,820	1,820
Property, Plant and Equipment, Other, Accumulated Depreciation	1,261	1,096
Net Book Value	$559	$724

Property_and_Equipment_Schedul

Property and Equipment: Schedule of Cost Method Investments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Leasehold Improvements	'	'
Property Plant and Equipment Useful Life	10	10
Deferred Costs, Noncurrent	$84,816	$79,866
Property, Plant and Equipment, Other, Accumulated Depreciation	36,477	28,516
Net Book Value	48,339	51,350
Furniture and Equipment	'	'
Property Plant and Equipment Useful Life	7	7
Deferred Costs, Noncurrent	28,652	20,001
Property, Plant and Equipment, Other, Accumulated Depreciation	8,262	5,659
Net Book Value	20,390	14,342
Lab Equipment	'	'
Property Plant and Equipment Useful Life	5	5
Deferred Costs, Noncurrent	14,448	14,448
Property, Plant and Equipment, Other, Accumulated Depreciation	5,626	2,628
Net Book Value	8,822	11,820
Computer Equipment	'	'
Property Plant and Equipment Useful Life	2.5	2.5
Deferred Costs, Noncurrent	1,820	1,820
Property, Plant and Equipment, Other, Accumulated Depreciation	1,261	1,096
Net Book Value	$559	$724

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Details	'	'	'	'
Depreciation	$4,401	$5,235	$13,137	$14,584

Equity_Method_Investment_Detai

Equity Method Investment (Details) (USD $)	36 Months Ended
	Nov. 30, 2014	Dec. 31, 2011
Details	'	'
Sublicense Agreement	40,000,000	'
Sublicense Fee	$960,000	'
Sublicensing Revenue	'	$1,000,000

Equity_Method_Investment_Equit1

Equity Method Investment: Equity Investment in Laboratories (Details) (USD $)	9 Months Ended
	Sep. 30, 2014		Dec. 31, 2013
Details	'		'
Equity method investment	$909,968	[1]	$911,672	[1]
Equity Loss	($1,704)		'
[1]	See Note 5

Equity_Method_Investment_Summa2

Equity Method Investment: Summarized Balance Sheets Text Block (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
Cash	$52,208		$2,309,563
TOTAL CURRENT ASSETS	482,219		2,492,134
Total Assets	51,470,297		53,482,042
Due to related parties, current	986,453	[1]	853,740	[1]
License fee payable, current	'	[2]	574,211	[2]
TOTAL LIABILITIES	2,317,708		2,818,025
Capital Stock	106,748	[3]	105,998	[3]
Additional paid-in capital	56,322,833		55,145,783
Accumulated deficit	-7,331,646		-4,720,970
Total Stockholders' Equity	49,152,589		50,664,017
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	51,470,297		53,482,042
Summarized Balance Sheets	'		'
Cash	111,408		-8,569
TOTAL CURRENT ASSETS	111,408		-8,569
Intangible Assets, Current	1,025,152		1,025,152
Total Assets	1,136,560		1,016,583
Accounts Payable, Current	17,574		43,300
Due to related parties, current	199,111		50,000
Liabilities, Current	216,685		93,300
License fee payable, current	976,320		976,320
TOTAL LIABILITIES	1,236,623		1,069,620
Capital Stock	80,000		80,000
Additional paid-in capital	43,618		43,618
Accumulated deficit	-180,063		-176,655
Total Stockholders' Equity	-100,063		-53,037
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$1,136,560		$1,016,583
[1]	See Note 9
[2]	See Note 6
[3]	$0.001 par value; 300,000,000 shares authorized; 106,747,586 issued and outstanding (December 31, 2013- 105,997,586); See Note 7

Equity_Method_Investment_Summa3

Equity Method Investment: Summarized Statement of Operations Text Block (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	'	'	'	'
General and administrative	677,249	336,063	2,595,835	836,601
TOTAL OPERATING EXPENSES	681,650	341,298	2,608,972	851,185
Net Loss	-681,674	-341,411	-2,610,676	-845,652
Summarized Statements of Operation	'	'	'	'
Revenue	'	11,455	'	11,455
General and administrative	48	11,681	3,408	389
TOTAL OPERATING EXPENSES	48	11,681	3,408	389
Net Loss	($48)	($226)	($3,408)	$11,066

Intangibles_and_License_Fee_Pa1

Intangibles and License Fee Payable (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Jul. 09, 2014	Dec. 31, 2013	Aug. 13, 2013	Jul. 26, 2013	Jul. 08, 2013	Jun. 04, 2013	31-May-13	Apr. 29, 2013	Mar. 31, 2013	Mar. 24, 2010
Details	'	'	'	'	'	'	'	'	'	'	'
Common Stock, Shares Issued	106,747,586	750,000	105,997,586	100,000	100,000	680,000	20,000	860,000	1,184,000	40,000	35,500,000
License Fee	'	'	'	'	'	'	'	'	'	'	$2,500,000
License Fee Payable	636,100	'	'	'	'	'	'	'	'	'	'
License Fee Receivable	$61,889	'	'	'	'	'	'	'	'	'	'

Capital_Stock_Details

Capital Stock (Details) (USD $)

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

Apr. 10, 2014

Sep. 30, 2014

Sep. 30, 2013

Jul. 09, 2014

Dec. 31, 2013

Aug. 13, 2013

Jul. 26, 2013

Jul. 08, 2013

Jun. 04, 2013

31-May-13

22-May-13

Apr. 29, 2013

Mar. 31, 2013

Mar. 27, 2013

Mar. 22, 2013

Feb. 28, 2013

Feb. 25, 2013

Mar. 24, 2010

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Current Period Grants

Current Period Grants

Current Period Grants

Current Period Grants

Warrants

Warrants

Stock Options

Stock Options

Common Stock, Shares Issued

'

106,747,586

'

750,000

105,997,586

100,000

100,000

680,000

20,000

860,000

'

1,184,000

40,000

'

'

'

'

35,500,000

'

'

'

'

'

'

'

'

Issuance for Common Stock for Cash

'

'

'

$375,000

'

$50,000

$50,000

$287,105

$10,000

$380,000

'

$592,000

$20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

5,800,000

4,500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

$0.55

$0.55

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

5.64

7.57

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,300,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-500,000

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

'

'

'

Shares, Issued

'

'

'

'

'

'

'

'

'

'

200,000

'

'

600,000

200,000

200,000

200,000

'

'

'

'

'

'

'

'

'

Common Stock Shares Issued For Cash

'

'

'

'

'

'

'

'

'

'

50,000

'

'

152,895

50,000

50,000

50,000

'

'

'

'

'

'

'

'

'

Fair Market Value Options

802,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

$0.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

$0.62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

0.37%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

242.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

1,177,800

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

0

'

'

'

'

Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$802,800

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.55

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.53

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
	Sep. 30, 2014
Details	'
Other Comprehensive Income (Loss), Tax	$5,000,000

Related_Party_Transacations_Sc2

Related Party Transacations: Schedule of Accounts, Notes, Loans and Financing Receivable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Dr. Ronald H. Stead	'	'
Related Party Transaction, Due from (to) Related Party	$62,454	'
Related Party Transaction, Due from (to) Related Party	-62,454	'
Dr. Ghanbari	'	'
Related Party Transaction, Due from (to) Related Party	52,795	-55,635
Related Party Transaction, Due from (to) Related Party	-52,795	55,635
Panacea Labs	'	'
Related Party Transaction, Due from (to) Related Party	-177,646	-77,896
Related Party Transaction, Due from (to) Related Party	177,646	77,896
Total Accounts Receivable	'	'
Related Party Transaction, Due from (to) Related Party	-292,895	-133,531
Related Party Transaction, Due from (to) Related Party	$292,895	$133,531

Related_Party_Transacations_Sc3

Related Party Transacations: Schedule of Related Party Transactions (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Dr. Moshiri CEO	'	'
Related Party Transaction, Due from (to) Related Party	$178,440	$2,256
668152 Ontario Ltd.	'	'
Related Party Transaction, Due from (to) Related Party	808,013	851,484
Total	'	'
Related Party Transaction, Due from (to) Related Party	$986,453	$853,740

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Details	'	'
Operating Leases, Rent Expense	$54,407	$246,062